Printer Friendly

FDA conditionally OKs third AIDS drug.

The drug zalcitabine--also known as dideoxycytidine (DDC) --last week became the third drug approved by the Food and Drug Administration for combating infection with HIV, the virus that causes AIDS.

However, since tests of zalcitabine are still in progress, the FDA approved the drug's use only in combination with the AIDS drug zidovudine, or AZT. The agency also suggested that physicians use zalcitabine only for AIDS patients whose counts of CD4 cells, a key immune system component, have dropped below 300 per cubic millimeter of blood.

The FDA based its approval on data from two small studies--each with fewer than 100 patients--and said it would review the decision within six months, based on the outcome of a larger, ongoing trial. The small studies indicated that a combination of zidovudine and zalcitabine could raise the CD4 counts of AIDS patients. An earlier study suggested the drug combo could also improve neurological AIDS symptoms (SN: 9/10/88, p.172).
COPYRIGHT 1992 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:dideoxycytidine
Publication:Science News
Article Type:Brief Article
Date:Jul 4, 1992
Previous Article:No go for fetal tissue transplantation.
Next Article:Sinking solution for carbon dioxide.

Related Articles
AIDS: treatment and transmission.
AIDS drug approval recommended.
AIDS drug approved, vaccine tested.
HIV-2 case found, AIDS drug tested.
Two AIDS drugs may be better than one.
Proposal seeks wider access to AIDS drugs.
AIDS drug finds a booster in FDA panel.
FDA: New Email List on HIV/AIDS.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters